Sendero Wealth Management LLC Acquires 12,142 Shares of Novo Nordisk A/S (NYSE:NVO)

Sendero Wealth Management LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 35.4% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 46,413 shares of the company’s stock after acquiring an additional 12,142 shares during the quarter. Sendero Wealth Management LLC’s holdings in Novo Nordisk A/S were worth $3,992,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $25,000. Daiwa Securities Group Inc. bought a new stake in Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP purchased a new position in shares of Novo Nordisk A/S in the 3rd quarter worth about $42,000. Carolina Wealth Advisors LLC bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $48,000. Finally, M&R Capital Management Inc. raised its holdings in shares of Novo Nordisk A/S by 260.5% during the 3rd quarter. M&R Capital Management Inc. now owns 411 shares of the company’s stock valued at $49,000 after buying an additional 297 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 2.2 %

Shares of NYSE:NVO opened at $82.99 on Thursday. The stock’s 50-day moving average is $99.26 and its 200 day moving average is $118.18. The company has a market cap of $372.42 billion, a PE ratio of 26.86, a P/E/G ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $80.05 and a 1 year high of $148.15.

Analyst Ratings Changes

A number of research analysts have commented on NVO shares. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.